日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Hyperglutaminolysis drives senescence and aging through arginine-mTORC1 axis activation.

谷氨酰胺分解过度通过精氨酸-mTORC1轴激活驱动衰老。

Chen Honghan, Huang Ning, Xu Weitong, Yang Yu, Wang Fangfang, Gong Hui, Zhou Jiao, Tai Haoran, Zhao Tingting, Zhang Jian, Li Ying, Liang Ge, Tang Minghai, Li Jie, Yang Ming, Liu Jin, Huang Xiaoli, Xiao Hengyi

Covalent modification of Keap1 Cys489 by NU6300 activates Nrf2 signaling and suppresses NLRP3 inflammasome-mediated pyroptosis

NU6300 对 Keap1 Cys489 的共价修饰激活 Nrf2 信号通路并抑制 NLRP3 炎症小体介导的细胞焦亡

Jiang, Xueqin; Zheng, Hongyu; Zhang, Xinlu; Tang, Minghai; Peng, Jing; Cai, Xiaoying; Su, Kaiyue; Zhang, Ruijia; Ye, Neng; Lin, Lei; Ma, Rupei; Shen, Caiyun; Wu, Wenshuang; Ye, Haoyu

Preclinical and first-in-human of purinostat mesylate, a novel selective HDAC I/IIb inhibitor, in relapsed/refractory multiple myeloma and lymphoma.

普利诺他甲磺酸盐(一种新型选择性 HDAC I/IIb 抑制剂)在复发/难治性多发性骨髓瘤和淋巴瘤中的临床前和首次人体试验

Yang Linyu, Qiu Qiang, Wang Jie, Wen Yi, Li He, Liang Rui, Feng Yunyu, Wang Fang, Lin Xiaojing, Tang Minghai, Yang Jianhong, Pei Heying, Zhao Peng, Wang Jishi, Xiang Jin, Miao Jia, Zheng Li, Tan Ke, Wang Yongsheng, Hu Yiguo, Chen Lijuan, Zhao Weili, Niu Ting

CMD-OPT model enables the discovery of a potent and selective RIPK2 inhibitor as preclinical candidate for the treatment of acute liver injury.

CMD-OPT 模型能够发现一种强效且选择性的 RIPK2 抑制剂,作为治疗急性肝损伤的临床前候选药物

Chen Yong, Yuan Xue, Yan Wei, Zou Yurong, Wei Haoche, Wei Yuhan, Tang Minghai, Chen Yulian, Ma Ziyan, Yang Tao, Liu Kongjun, Xiong Baojian, Hu Xiuying, Yang Jianhong, Chen Lijuan

Identification of a ligand-binding site on tubulin mediating the tubulin-RB3 interaction

鉴定出微管蛋白上介导微管蛋白-RB3相互作用的配体结合位点。

Li, Yong; Zhang, Chufeng; Tang, Dongmei; Wang, Tao; Yan, Wei; Yang, Linyu; Bai, Peng; Tang, Minghai; Pei, Heying; Chen, Lijuan; Chen, Qiang; Yang, Jianhong

Correction to: Preclinical studies of Flonoltinib Maleate, a novel JAK2/FLT3 inhibitor, in treatment of JAK2(V617F)-induced myeloproliferative neoplasms

更正:新型 JAK2/FLT3 抑制剂马来酸氟诺替尼治疗 JAK2(V617F) 诱导的骨髓增生性肿瘤的临床前研究

Hu, Mengshi; Yang, Tao; Yang, Linyu; Niu, Lu; Zhu, Jinbing; Zhao, Ailin; Shi, Mingsong; Yuan, Xue; Tang, Minghai; Yang, Jianhong; Pei, Heying; Yang, Zhuang; Chen, Qiang; Ye, Haoyu; Niu, Ting; Chen, Lijuan

New Highly Potent NLRP3 Inhibitors: Furanochalcone Velutone F Analogues

新型高效NLRP3抑制剂:呋喃查尔酮Velutone F类似物

Zhang, Ruijia; Hong, Feng; Zhao, Min; Cai, Xiaoying; Jiang, Xueqin; Ye, Neng; Su, Kaiyue; Li, Na; Tang, Minghai; Ma, Xu; Ni, Hengfan; Wang, Lun; Wan, Li; Chen, Lijuan; Wu, Wenshuang; Ye, Haoyu

Therapeutic efficacy of an injectable formulation of purinostat mesylate in SU-DHL-6 tumour model

注射用普利诺司他甲磺酸盐制剂在SU-DHL-6肿瘤模型中的治疗效果

Zhu, Zejiang; Wen, Jiaolin; Xu, Yaohui; Pei, Heying; Li, Dan; Tang, Minghai; Bai, Peng; He, Jun; Yang, Zhuang; Chen, Lijuan

Catalytic flexibility of rice glycosyltransferase OsUGT91C1 for the production of palatable steviol glycosides

水稻糖基转移酶OsUGT91C1在生产美味甜菊糖苷方面的催化灵活性

Zhang, Jinzhu; Tang, Minghai; Chen, Yujie; Ke, Dan; Zhou, Jie; Xu, Xinyu; Yang, Wenxian; He, Jianxiong; Dong, Haohao; Wei, Yuquan; Naismith, James H; Lin, Yi; Zhu, Xiaofeng; Cheng, Wei

Cevipabulin-tubulin complex reveals a novel agent binding site on α-tubulin with tubulin degradation effect

Cevipabulin-微管蛋白复合物揭示了α-微管蛋白上一个新的药物结合位点,并具有微管蛋白降解作用。

Yang, Jianhong; Yu, Yamei; Li, Yong; Yan, Wei; Ye, Haoyu; Niu, Lu; Tang, Minghai; Wang, Zhoufeng; Yang, Zhuang; Pei, Heying; Wei, Haoche; Zhao, Min; Wen, Jiaolin; Yang, Linyu; Ouyang, Liang; Wei, Yuquan; Chen, Qiang; Li, Weimin; Chen, Lijuan